Massachusetts Department of Public Health (MDPH)

Immunization Division

**Childhood Vaccine Availability Table**

**Eligibility Categories:**

* **All Children:** Vaccine provided by MDPH for identified cohorts, regardless of insurance status.
* **Vaccines for Children (VFC) Program Only:** Vaccine provided by MDPH for identified cohorts who are: 1) uninsured; 2) enrolled in MassHealth/Medicaid; 3) American Indian or Alaska Native; or 4) underinsured (insurance does not cover the vaccine) andseen at a federally qualified community health center. (Vaccines available only for VFC eligible groups appear shaded)

|  |  |  |
| --- | --- | --- |
| **Vaccine** | **Eligibility** | **DPH-Supplied Vaccine Available For:** |
| **DT** | All | * Children aged 2 months – 6 years for whom pertussis vaccine is contraindicated
 |
| **DTaP** | All | * All children aged 2 months – 6 years
 |
| **DTaP-Hep B-IPV** (Pediarix®) | All | * All children aged 2 months – 6 years for the first 3 doses of DTaP and IPV and any dose of Hep B at 2, 4 and 6 months
* Not approved for dose 4 or 5 of the DTaP series or dose 4 of the IPV series
 |
| **DTaP-IPV-Hib**(Pentacel®) | All | * All children aged 2 months – 4 years for the first 4 doses of DTaP, IPV and Hib at 2, 4, 6 and 15 – 18 months
 |
| **DTaP-IPV**(Kinrix®) | All | * All children aged 4 – 6 years for routine immunization for the 5th dose of the DTaP series and 4th dose of the IPV series
* Not approved for the first 3 doses of DTaP and IPV or dose 4 of the DTaP series
 |
| **Hep A** | All | * Routine vaccination of the 1st and 2nd dose for children aged 12 – 23 months
* Catch-up vaccination of children aged 2 – 18 years
 |
| **Hep B** | All | * All children through 18 years of age
 |
| **Hib** | All | * All children aged 2 – 59 months
* Children aged > 5 years in an ACIP-recommended group1
 |
| **HPV** | All  | * All children 9 – 18 years of age

Note: routinely recommended at 7th grade entry, 11 – 12 years of age  |
| **Influenza** | All | * All children aged 6 months through 18 years
 |
| **MCV4-ACWY**(Meningococcal Conjugate)(MDPH does not provide meningococcal polysaccharide vaccine) | All | * All adolescents 11 – 18 years of age

Note: first dose routinely recommended at 7th grade entry, 11 – 12 years of age, and second dose at 16 – 18 years of age * High risk1 children 2 months - 18 years, all doses, including boosters. Schedule depends on age and formulation. Note: Menveo approved beginning at 2 months and Menactra at 9 months. High risk includes: functional or anatomic asplenia (sickle cell), complement deficiencies, travelers, occupational risk, outbreaks.
 |

|  |  |  |
| --- | --- | --- |
| **Vaccine** | **Eligibility** | **DPH Supplied Vaccine Available For:** |
| **MenB** | All | High risk children 10 – 18 years of age in the following risk groups: * Persistent complement component deficiencies (including: inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or taking eculizumab [Soliris®]).
* Anatomic or functional asplenia (including: sickle cell).
* Microbiologists routinely exposed to isolates of Neisseria meningitidis.
* Identified as at increased risk because of a serogroup B meningococcal disease outbreak.

Children enrolled in Children’s Medical Security Plan (CMSP) and sCHIP are also covered using *state* funds. |
| VFC Only2 | * May be considered for healthy adolescents 16 – 18 years of age to provide short term protection against most strains of serogroup B meningococcal disease (individual clinical decision-making).
 |
| **MMR** | All | * All children aged 12 months – 18 years
 |
| **MMRV**  | All | * All children aged 12 months – 12 years who require both MMR and varicella vaccines

Note: ACIP recommends the 1st dose in the series for children 12 – 47 months be given as separate injections of MMR and varicella vaccines and generally recommends MMRV for the 2nd dose in the series or for the 1st dose for those > 48 months. See [ACIP](http://www.cdc.gov/mmwr/pdf/rr/rr5903.pdf) statement for full guidance.  |
| **PCV13**(Pneumococcal Conjugate) | All | * All children aged 2 – 59 months
* High risk1 children through age 71 months
* Subset of highest risk children aged 6 – 18 years
 |
| **PPSV23**(Pneumococcal Polysaccharide) | All | * Children aged 2 – 18 years who are in an ACIP recommended group1
 |
| **Polio** | All | * All children aged 2 months – 18 years
 |
| **Rotavirus** | All | * All infants aged 6 weeks – 8 months 0 days
 |
| **Td** | All | * All children aged 7 – 18 years
 |
| **Tdap** | All | * All children aged 7 – 18 years Note: routinely recommended at 7th grade entry, 11 – 12 years of age
 |
| **Varicella** | All | * All children aged 12 months – 18 years
 |

1High risk children as defined by the ACIP, including those exposed in an outbreak setting who are not fully vaccinated.

For a list of vaccines and the groups for whom vaccine is recommended, please see the MDPH *Summary of* *Advisory Committee on Immunization Practices (ACIP) Recommended Groups for Vaccination.* For the complete ACIP recommendations, see <http://www.cdc.gov/vaccines/acip/index.html>.

2Children with Medicaid as secondary insurance would be considered VFC-eligible.